COVAXIN and COVISHIELD has same licensure status now

The Central government on Thursday announced that Bharat Biotech’s indigenously developed COVAXIN has been moved out of the “clinical trial mode” and now COVAXIN has been granted the restricted emergency use authorization. The Dr.V K Paul who is the member (Health) NITI Aayog said that COVAXIN has been granted permission for restricted use in emergency situations in the public interest and both COVID-19 vaccines Bharat Biotech’s COVAXIN and COVISHIELD which manufactured by Serum Institute of India (SII) have the same licensure status now.

“The condition of it (Covaxin) being required to be administered under clinical trial mode is no more there,” said Dr.VK Paul

“Both the COVID-19 vaccines Covaxin and Covishield have the same licensure status. Covaxin has stood the test of time in terms of great safety. Only 311 individuals have minimal side effects. It is the triumph for India’s research and development enterprise and Science and technology enterprise.” Dr.Paul added

Also Read : Breaking- India reports 23,285 new COVID-19 case-https://www.medicallyspeaking.in/covid-news-updates/breaking-india-reports-23285-new-covid-19-cases/